Elbasvir and grazoprevir for the treatment of hepatitis C

被引:1
作者
Wang, Szu-Jen [1 ,2 ]
Huang, Chung-Feng [3 ,4 ]
Yu, Ming-Lung [1 ,3 ,4 ]
机构
[1] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan
[2] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Kaohsiung, Taiwan
关键词
Direct-acting antivirals; elbasvir; grazoprevir; hepatitis C virus; genotype; 1; or; 4; sustained viral response; efficacy; safety; tolerability; drug-drug interaction; VIRUS GENOTYPE 1; HCV NS5A INHIBITOR; INFECTION; ELBASVIR/GRAZOPREVIR; ASSOCIATION; EFFICACY; MK-8742; SAFETY; TRANSPLANTATION; COINFECTION;
D O I
10.1080/14787210.2021.1874351
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations. Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR). Expert opinion: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.
引用
收藏
页码:1071 / 1081
页数:11
相关论文
共 50 条
[21]   Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease [J].
Reddy, K. Rajender ;
Roth, David ;
Bruchfeld, Annette ;
Hwang, Peggy ;
Haber, Barbara ;
Robertson, Michael N. ;
Barr, Eliav ;
Greaves, Wayne .
HEPATOLOGY RESEARCH, 2017, 47 (12) :1340-1345
[22]   Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection [J].
Puenpatom, Amy ;
Cao, Yumei ;
Yu, Xian ;
Kanwal, Fasiha ;
El-Serag, Hashem B. ;
Kramer, Jennifer R. .
INFECTIOUS DISEASES AND THERAPY, 2020, 9 (02) :355-365
[23]   Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan [J].
Toyoda, Hidenori ;
Atsukawa, Masanori ;
Takaguchi, Koichi ;
Senoh, Tomonori ;
Michitaka, Kojiro ;
Hiraoka, Atsushi ;
Fujioka, Shinichi ;
Kondo, Chisa ;
Okubo, Tomomi ;
Uojima, Haruki ;
Tada, Toshifumi ;
Yoneyama, Hirohito ;
Watanabe, Tsunamasa ;
Asano, Toru ;
Ishikawa, Toru ;
Tamai, Hideyuki ;
Abe, Hiroshi ;
Kato, Keizo ;
Tsuji, Kunihiko ;
Ogawa, Chikara ;
Shimada, Noritomo ;
Iio, Etsuko ;
Deguchi, Akihiro ;
Itobayashi, Ei ;
Mikami, Shigeru ;
Moriya, Akio ;
Okubo, Hironao ;
Tani, Joji ;
Tsubota, Akihito ;
Tanaka, Yasuhito ;
Masaki, Tsutomu ;
Iwakiri, Katsuhiko ;
Kumada, Takashi .
JOURNAL OF GASTROENTEROLOGY, 2018, 53 (12) :1276-1284
[24]   US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection [J].
Boyd, Sarita D. ;
Tracy, LaRee ;
Komatsu, Takashi E. ;
Harrington, Patrick R. ;
Viswanathan, Prabha ;
Murray, Jeff ;
Sherwat, Adam .
CLINICAL DRUG INVESTIGATION, 2017, 37 (04) :317-326
[25]   An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection [J].
Lee, Youn Jae ;
Heo, Jeong ;
Kim, Do Young ;
Chung, Woo Jin ;
Tak, Won Young ;
Kim, Yoon Jun ;
Paik, Seung Woon ;
Sim, Eungeol ;
Kulasingam, Susila ;
Talwani, Rohit ;
Haber, Barbara ;
Hwang, Peggy .
CLINICAL AND MOLECULAR HEPATOLOGY, 2019, 25 (04) :400-407
[26]   Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects [J].
Hsieh, Yi-Chung ;
Lin, Chih-Lang ;
Hung, Chao-Hung ;
Chen, Chien-Hung ;
Tung, Shui-Yi ;
Lin, Chun-Yen ;
Hu, Tsung-Hui ;
Lu, Sheng-Nan ;
Chien, Rong-Nan ;
Sheen, I-Shyan .
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (05) :505-513
[27]   Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation [J].
Miuma, Satoshi ;
Miyaaki, Hisamitsu ;
Soyama, Akihiko ;
Hidaka, Masaaki ;
Takatsuki, Mitsuhisa ;
Shibata, Hidetaka ;
Taura, Naota ;
Eguchi, Susumu ;
Nakao, Kazuhiko .
HEPATOLOGY RESEARCH, 2018, 48 (12) :1045-1054
[28]   Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers [J].
Feng, Hwa-Ping ;
Caro, Luzelena ;
Fandozzi, Christine ;
Chu, Xiaoyan ;
Guo, Zifang ;
Talaty, Jennifer ;
Panebianco, Deborah ;
Dunnington, Katherine ;
Du, Lihong ;
Hanley, William D. ;
Fraser, Iain P. ;
Mitselos, Anna ;
Denef, Jean-Francois ;
De Lepeleire, Inge ;
de Hoon, Jan N. ;
Vandermeulen, Corinne ;
Marshall, William L. ;
Jumes, Patricia ;
Huang, Xiaobi ;
Martinho, Monika ;
Valesky, Robert ;
Butterton, Joan R. ;
Iwamoto, Marian ;
Yeh, Wendy W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)
[29]   Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial [J].
Dore, Gregory J. ;
Altice, Frederick ;
Litwin, Alain H. ;
Dalgard, Olav ;
Gane, Edward J. ;
Shibolet, Oren ;
Luetkemeyer, Anne ;
Nahass, Ronald ;
Peng, Cheng-Yuan ;
Conway, Brian ;
Grebely, Jason ;
Howe, Anita Y. M. ;
Gendrano, Isaias N. ;
Chen, Erluo ;
Huang, Hsueh-Cheng ;
Dutko, Frank J. ;
Nickle, David C. ;
Bach-Yen Nguyen ;
Wahl, Janice ;
Barr, Eliav ;
Robertson, Michael N. ;
Platt, Heather L. .
ANNALS OF INTERNAL MEDICINE, 2016, 165 (09) :625-+
[30]   Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review [J].
Liu, Jinyu ;
Guo, Min ;
Ke, Lei ;
You, Ruxu .
FRONTIERS IN PUBLIC HEALTH, 2022, 10